Document is current
Any future updates will be listed below
-
Authors
Graziano, Vincent R.
Porat, Jennifer https://orcid.org/0000-0002-1709-4635
Ah Kioon, Marie Dominique https://orcid.org/0000-0003-2319-0444
Mejdrová, Ivana
Matz, Alyssa J.
Lebedenko, Charlotta G.
Chai, Peiyuan
Pluvinage, John V. https://orcid.org/0000-0002-9607-2783
Ricci-Azevedo, Rafael https://orcid.org/0000-0002-0020-6530
Harrison, Andrew G.
Wright, Skylar S. https://orcid.org/0000-0002-1341-5710
Wang, Xinzheng
Strine, Madison S. https://orcid.org/0000-0001-8572-1314
Wang, Penghua https://orcid.org/0000-0002-7332-1871
Wilson, Michael R. https://orcid.org/0000-0002-8705-5084
Vanaja, Sivapriya Kailasan https://orcid.org/0000-0001-6188-2869
Zhou, Beiyan https://orcid.org/0000-0003-0638-2428
Barrat, Franck J. https://orcid.org/0000-0002-0735-0850
Carell, Thomas https://orcid.org/0000-0001-7898-2831
Flynn, Ryan A. https://orcid.org/0000-0001-5013-0442
Rathinam, Vijay A. https://orcid.org/0000-0002-8009-3977
- License Information
-
More Information
Article History
Received: 5 June 2024
Accepted: 19 June 2025
First Online: 6 August 2025
Competing interests
: R.A.F. is a stockholder of ORNA Therapeutics. R.A.F. is a board of directors’ member and stockholder of Chronus Health and Blue Planet Systems. V.R.G., R.A.F. and V.A.R. have filed a patent on the sequences and use of acp3U in various functional immune applications. The other authors declare no competing interests.
